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The endogenous metabolite itaconate has recently emerged as a regulator of 43 
macrophage function but the precise mechanism of action remains poorly 44 
understood1-3. We report that itaconate is required for the activation of the anti-45 
inflammatory transcription factor nuclear factor-erythroid 2 p45-related factor 2 46 
(Nrf2) by LPS. We find that itaconate directly modifies proteins via alkylation of 47 
cysteine residues. Itaconate alkylates cysteines 151, 257, 288, 273 and 297 on 48 
 2 
Kelch-Like ECH-Associated Protein 1 (Keap1) enabling Nrf2 to increase 49 
expression of down-stream genes with anti-oxidant and anti-inflammatory 50 
capacity. The activation of Nrf2 is required for the anti-inflammatory action of 51 
itaconate. We describe the use of a new cell-permeable itaconate derivative, 4-52 
octyl itaconate (OI), which is protective against LPS-induced lethality in vivo 53 
and decreases cytokine production. We show that type I interferons (IFN) 54 
boost immunoresponsive gene 1 (Irg1) expression and itaconate production. 55 
Furthermore, we find that itaconate production limits the type I IFN response 56 
indicating a negative feedback loop involving IFNs and itaconate. Our findings 57 
demonstrate that itaconate is a critical anti-inflammatory metabolite acting via 58 
Nrf2 to limit inflammation and modulate type I IFNs.  59 
 60 
Macrophages have a key role in innate immunity. They respond rapidly to pathogens 61 
and subsequently promote an anti-inflammatory phenotype to limit damage and 62 
promote tissue repair. The factors driving these changes are incompletely 63 
understood. Itaconate, a metabolite synthesized by the enzyme encoded by Irg11, is 64 
elevated in LPS-activated macrophages2 and has been suggested to limit 65 
inflammation by inhibiting succinate dehydrogenase (SDH), a critical pro-66 
inflammatory regulator4, however, the details remain unclear.  67 
Itaconate was the most abundant metabolite in LPS-treated human 68 
macrophages (Fig. 1a) and reached 5 mM in murine bone marrow-derived 69 
macrophages (BMDMs) following LPS stimulation (Fig. 1b, c). Itaconate can disrupt 70 
SDH activity, but is less potent than the classic SDH inhibitor malonate (Extended 71 
Data Fig. 1), suggesting that it may exert its anti-inflammatory effects via additional 72 
mechanisms.  73 
Itaconate contains an electrophilic ,-unsaturated carboxylic acid that could 74 
potentially alkylate protein cysteine residues by a Michael addition to form a 2,3-75 
dicarboxypropyl adduct. An attractive candidate protein that undergoes cysteine 76 
alkylation is Keap1, a central player in the anti-oxidant response (Fig. 1d). Keap1 77 
normally associates with and promotes the degradation of Nrf2, however alkylation of 78 
critical Keap1 cysteines allows newly synthesized Nrf2 to accumulate, migrate to the 79 
nucleus and activate a transcriptional antioxidant and anti-inflammatory programme5. 80 
We therefore examined Keap1/Nrf2 as a target of itaconate. 81 
The cell-permeable itaconate derivative, dimethyl itaconate (DMI)3 boosted 82 
levels of Nrf2 protein, expression of downstream target genes, including heme-83 
oxygenase (Hmox)1, and glutathione (GSH) (Extended Data Fig. 2a-d). However, the 84 
lack of a negative charge on the conjugated ester group in DMI increases its 85 
reactivity towards Michael addition, making it a far superior Nrf2 activator than 86 
itaconate akin to the potent Nrf2 activator dimethylfumarate (DMF)6. DMI is rapidly 87 
degraded within cells without releasing itaconate7, hence is unlikely to mimic 88 
endogenous itaconate. Even so, these data indicate that Nrf2 activation is anti-89 
inflammatory (Extended Data Fig. 2e, f)8. 90 
To overcome the limitations of DMI, we synthesised 4-octyl itaconate (OI), a 91 
cell-permeable itaconate derivative (Extended Data Fig. 3a). Itaconate and OI had 92 
similar thiol reactivity that was far lower than that of DMI (Extended Data Fig. 3b, c, 93 
g), making it a suitable cell-permeable itaconate surrogate. Furthermore, OI was 94 
hydrolysed to itaconate by esterases in C2C12 cells (Extended Data Fig. 3d) and 95 
LPS-activated macrophages (Extended Data Fig. 3e). OI boosted Nrf2 levels (Fig 1e, 96 
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compare lane 5 to lane 1) and enhanced LPS-induced Nrf2 stabilisation (Fig. 1e, 97 
compare lane 6 to lane 2), increasing expression of down-stream target genes9, 98 
including the anti-inflammatory protein Hmox110 (Fig. 1f, g). We used a quantitative 99 
NAD(P)H:quinone oxidoreductase-1 (NQO1) inducer bioassay11,12, to assess potency 100 
of Nrf2 activation by the CD value (Concentration which Doubles the specific enzyme 101 
activity) for NQO1, the prototypical Nrf2 target gene. OI (CD = 2 μM), was more 102 
potent than the clinically used Nrf2 activator DMF (CD = 6.5 μM) (Fig. 1h, Extended 103 
Data Fig. 3g). OI stimulated GSH (a key anti-oxidant) synthesis (Extended Data Fig. 104 
3g- i). OI also boosted canonical activation of Nrf2 by the pro-oxidant hydrogen 105 
peroxide (H2O2) (Extended Data Fig. 3j, k). Importantly, 4-octyl 2-methylsuccinate 106 
(OMS) and octyl succinate (OS), related octyl esters, which are not Michael 107 
acceptors, had no effect on Nrf2 activity confirming the requirement for the itaconate 108 
moiety (Extended Data Fig. 3l). Dimethyl malonate (DMM), a potent SDH inhibitor4, 109 
did not activate Nrf2 (Extended Data Fig. 3m), confirming that Nrf2 activation by OI is 110 
independent of SDH inhibition.  111 
Itaconate is generated by Irg1 in the mitochondrial matrix and must cross the 112 
mitochondrial inner membrane (MIM) to act on Nrf2 in the cytosol. Itaconate is 113 
structurally similar to malate, which is transported across the MIM by the 114 
dicarboxylate (DIC), citrate (CTP) and oxoglutarate (OGC) carriers. All three carriers 115 
transported itaconate, whereas other tested carriers could not (Fig. 2a and Extended 116 
Data Fig. 4) suggesting that LPS-induced itaconate is generated in the mitochondrial 117 
matrix and is then exported to the cytosol to activate Nrf2.   118 
Our hypothesis is that itaconate activates Nrf2 by alkylation of Keap1 cysteine 119 
residue(s)13-15 akin to the modification of cysteines by fumarate (Extended Data Fig. 120 
5a). Cysteine 151 (Cys151) is a principal sensor on Keap1 for sulforaphane (SFN)16 121 
and DMF17. OI stabilized Nrf2-V5 in COS1 cells co-expressing wild-type Keap1 but 122 
not a Cys151S mutant, similarly to SFN (Fig. 2b, compare lanes 16 and 17 to lanes 123 
18 and 19). To analyse Keap1 alkylation directly, we overexpressed FLAG-tagged 124 
Keap1 in HEK293T cells and treated with OI. Tandem mass spectrometry (MS) of 125 
immunoprecipitated Keap1 revealed that for the Keap1 peptide (144-152), which 126 
contains Cys 151, OI treatment increased its mass by 242.15 Da, consistent with 127 
alkylation by OI (Fig. 2c). OI also modified other known Keap1 regulatory cysteine 128 
residues (Cys257, Cys288 and Cys273) (Extended Data Fig.5b-d, Extended Data 129 
Table 1a). Furthermore, itaconate-cysteine adducts, derived in part from glucose and 130 
glutamine (Fig. 2d and Extended Data Fig. 6), were detected in LPS-treated 131 
macrophages. These data suggest that itaconate activates Nrf2 by alkylating Keap1 132 
cysteines. We further explored cysteine alkylation induced by itaconate using an 133 
untargeted MS approach in macrophages treated with OI, or with LPS which elevates 134 
itaconate levels. We identified a number of proteins containing alkylated cysteine 135 
residues (Extended Data Table 1b, c). Notably Ldha, which has a critical role in the 136 
regulation of glycolysis, was alkylated in OI- and LPS-treated macrophages (Fig. 2e 137 
and Extended Data Fig. 5e, f). This modification, here defined as 2,3-138 
dicarboxypropylation, generates a stable thioether. As there are no known pathways 139 
of removal of such PTMs modified proteins are likely degraded, suggesting this 140 
modification will have profound effects on macrophage function. 141 
 We next assessed whether itaconate activation of Nrf2 could be anti-142 
inflammatory. OI, used at concentrations which did not affect cellular viability, 143 
decreased LPS-induced IL-1 mRNA, pro-IL-1 and HIF-1 protein levels, 144 
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extracellular acidification rate (ECAR) and IL-10 yet had no effect on NFB activity or 145 
TNF- (Fig. 3a, b and Extended Data Fig. 7a-f). OI also decreased IL-1 mRNA in 146 
BMDMs treated with the TLR2 and TLR3 ligands, Pam3CSK and poly I:C, 147 
respectively (Extended Data Fig. 7g). LPS-induced ROS, nitric oxide (NO) and iNOS 148 
levels were limited by OI (Fig. 3c, d and Extended Data Fig. 7h, i). These effects are 149 
likely to be a consequence of ROS detoxification following Nrf2 induction by OI. IL-1 150 
and TNF- were decreased by OI in human PBMCs (Fig. 3e, Extended Data Fig. 7j). 151 
OI also counteracted the pro-inflammatory response to LPS in vivo. OI, which 152 
activated Nrf2 (Extended Data Fig. 7k), prolonged survival, decreased clinical score 153 
and improved body temperature regulation, and decreased IL-1 and TNF-α levels 154 
but not IL-10 in an LPS lethality model (Fig. 3f, g and Extended Data Fig. 8f).  155 
OI induction of Hmox1 was blocked in Nrf2-deficient macrophages (Fig. 3h 156 
(compare lanes 2, 3 to lanes 8, 9) and Extended Data Fig. 8f) or when Nrf2 was 157 
silenced (Extended Data Fig. 8a, d (compare lanes 7, 8 to lanes 11, 12)). Without 158 
Nrf2, the decrease in LPS-induced IL-1β with OI was significantly impaired (Fig. 3h 159 
(compare lane 6 to lane 12), Extended Data Fig. 8f and 8b-e (compare lanes 6 and 8 160 
to 10 and 12)). Furthermore, two Nrf2 activators, diethyl maleate (DEM) and 15-161 
deoxy-Δ12,14-prostaglandin J2 (J2) decreased LPS-induced IL-1β, IL-10, Nos2 and 162 
NO (Extended Data Fig. 8g-k). Thus, itaconate activates an anti-inflammatory 163 
programme through Nrf2.  164 
We next investigated how switching from a pro- to an anti-inflammatory state 165 
might affect itaconate production from aconitate by Irg1. By modelling gene networks 166 
controlling Irg1 expression, Tallam and colleagues (2016) identified IFN response 167 
factor (Irf1) as a regulator18. Here we show that itaconate levels are increased 168 
following IFN-β treatment (Fig. 4a), in agreement with others19. Levels of citrate and 169 
aconitate, the substrate for Irg1, were reduced by IFN-β as was the downstream 170 
metabolite α-ketoglutarate (α-KG) (Extended Data Fig. 9a). These data are 171 
consistent with an increase in aconitate conversion to itaconate rather than α-KG. 172 
IFN-β enhanced basal and LPS-induced Irg1 expression (Fig. 4b). LPS and poly I:C-173 
induced Irg1 expression in BMDMs lacking type I IFN receptor was decreased (Fig. 174 
4c), indicating that autocrine IFN facilitates Irg1 induction. OI limited the IFN 175 
response, decreasing IFN-β and IFN-stimulated gene (ISG)20 expression and I-176 
kappa-B kinase (IKK)- and ISG15 protein, IFN-β production in poly I:C-treated 177 
PBMCs and LPS-induced IFN-β production in vivo (Fig. 4d-g and Extended Data Fig. 178 
9b, c). IFN-β enhanced IL-10 mRNA and protein expression ± LPS (Extended Data 179 
Fig. 9d), suggesting that the decrease in IL-10 following OI treatment is due to 180 
reduced type I IFN production 20. Nrf2 knock-out or knockdown attenuated the 181 
reduction of ISG20 expression by OI while the Nrf2 activators, DEM and J2, reduced 182 
ISG20 expression (Extended Data Fig. 9e-g). This agrees with increased expression 183 
of IRF3-regulated genes in LPS-treated Nrf2-deficient mice21.  184 
These data suggest the operation a negative feedback loop: itaconate is 185 
generated in response to LPS, in part through type I IFNs, and promotes an anti-186 
inflammatory programme by Nrf2 activation (Fig. 4h), as well as SDH inhibition3,22. 187 
This limits further inflammatory gene expression and its own production by down-188 
regulating the IFN response. This helps explain why Nrf2-deficient mice are more 189 
sensitive to septic shock21, even though under certain circumstances these mice are 190 
protected from inflammation23. Our identification of itaconate as an inflammatory 191 
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regulator, that directly modifies proteins through a newly identified post-translational 192 
modification, unveils therapeutic opportunities to use itaconate or OI to treat 193 
inflammatory diseases24. Most recently Shen and colleagues (2017) have made an 194 
intriguing link from itaconate to Vitamin B12 which warrants further investigation in 195 
the context of inflammation and immunity25. Further understanding the role of 196 
itaconate as an anti-inflammatory metabolite and regulator of type I IFNs is likely to 197 
yield new insights into the pathogenesis of inflammatory diseases. 198 
 199 
Author Contributions 200 
E. L. Mills and D. G. Ryan designed and performed experiments and analysed the 201 
data. E. L. Mills wrote the manuscript with assistance from all other authors. D. 202 
Menon, M. M. Hughes, M. C. Runtsch and A. F. McGettrick performed in vitro 203 
experiments using OI. R. G. Carroll, D. Sevin, A. S. H. Costa and C. Frezza assisted 204 
with the metabolomics analysis. Z. Zaslona, P. G. Fallon and E. Hams assisted with 205 
the in vivo mouse LPS trials. S. T. Caldwell and R. C. Hartley were responsible for 206 
the design and synthesis of octyl esters. H. A. Prag, E. R. S. Kunji, M. S.  King, and 207 
L. M. Booty assessed the effect of OI and itaconate on mitochondrial parameters and 208 
itaconate transport. D. Dikovskaya, M. Higgins and A. T. Dinkova-Kostova performed 209 
the Nqo1 assay and Keap1 WT and Cys151S mutant experiments. J. F. McGouran, 210 
R. Fisher, B. M. Kessler, E. T. Chouchani, M. P. Jedrychowski, J. Szpyt assisted with 211 
mass spectrometry experiments. L. Modis and G. Bruori provided guidance and 212 
advice. E. V. Knatko, P. J. Meakin, M. L. J. Ashford assisted with experiments in 213 
Nrf2-deficient mice. L. A. O’Neill conceived ideas and oversaw the research 214 
programme. M. P. Murphy provided advice, reagents and oversaw a portion of the 215 
work. 216 
 217 
Author Information 218 
Reprints and permissions information is available at www.nature.com/reprints. The 219 
authors declare no competing financial interests. Correspondence and requests for 220 
materials should be addressed to L. A. O’Neill. (laoneill@tcd.ie) 221 
 222 
Acknowledgements 223 
We thank Michael McMahon and John D. Hayes (University of Dundee) for plasmids, 224 
and Cancer Research UK (C20953/A18644) and the BBSRC (BB/L01923X/1) for 225 
financial support for ATDK. This work was supported by a Wellcome Trust 226 
Investigator award to RCH (110158/Z/15/Z), a grant to MPM from the Medical 227 
Research Council UK (MC_U105663142), a Wellcome Trust Investigator award to 228 
MPM (110159/Z/15/Z), and a grant to ERSK and MSK from the Medical Research 229 
Council UK (MC_U105663139). BMK and RF are supported by the Kennedy Trust 230 
Fund. We acknowledge Metabolon for their assistance with the metabolic work and 231 
analysis. The O’Neill lab acknowledges the following grant support: European 232 
Research Council (ECFP7-ERC-MICROINNATE), Science Foundation Ireland 233 
Investigator Award (SFI 12/IA/1531), GlaxoSmithKline Visiting Scientist 234 
Programme and The Wellcome Trust (oneill-wellcometrust-metabolic, grant number 235 
205455). ETC is supported by the Claudia Adams Barr Program. 236 
 237 
 238 
 6 
 239 
References 240 
 241 
1 Michelucci, A. et al. Immune-responsive gene 1 protein links metabolism to 242 
immunity by catalyzing itaconic acid production. Proc Natl Acad Sci U S A 243 
110, 7820-7825, doi:10.1073/pnas.1218599110 (2013). 244 
2 Strelko, C. L. et al. Itaconic acid is a mammalian metabolite induced during 245 
macrophage activation. J Am Chem Soc 133, 16386-16389, 246 
doi:10.1021/ja2070889 (2011). 247 
3 Lampropoulou, V. et al. Itaconate Links Inhibition of Succinate 248 
Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of 249 
Inflammation. Cell Metab 24, 158-166, doi:10.1016/j.cmet.2016.06.004 250 
(2016). 251 
4 Mills, E. L. et al. Succinate Dehydrogenase Supports Metabolic Repurposing 252 
of Mitochondria to Drive Inflammatory Macrophages. Cell 167, 457-470 e413, 253 
doi:10.1016/j.cell.2016.08.064 (2016). 254 
5 Hayes, J. D. & Dinkova-Kostova, A. T. The Nrf2 regulatory network provides 255 
an interface between redox and intermediary metabolism. Trends in 256 
biochemical sciences 39, 199-218, doi:10.1016/j.tibs.2014.02.002 (2014). 257 
6 Brennan, M. S. et al. Dimethyl fumarate and monoethyl fumarate exhibit 258 
differential effects on KEAP1, NRF2 activation, and glutathione depletion in 259 
vitro. PLoS One 10, e0120254, doi:10.1371/journal.pone.0120254 (2015). 260 
7 ElAzzouny, M. et al. Dimethyl Itaconate Is Not Metabolized into Itaconate 261 
Intracellularly. J Biol Chem 292, 4766-4769, doi:10.1074/jbc.C117.775270 262 
(2017). 263 
8 Kobayashi, E. H. et al. Nrf2 suppresses macrophage inflammatory response 264 
by blocking proinflammatory cytokine transcription. Nat Commun 7, 11624, 265 
doi:10.1038/ncomms11624 (2016). 266 
9 Lee, J. M., Calkins, M. J., Chan, K., Kan, Y. W. & Johnson, J. A. Identification 267 
of the NF-E2-related factor-2-dependent genes conferring protection against 268 
oxidative stress in primary cortical astrocytes using oligonucleotide 269 
microarray analysis. J Biol Chem 278, 12029-12038, 270 
doi:10.1074/jbc.M211558200 (2003). 271 
10 Piantadosi, C. A. et al. Heme oxygenase-1 couples activation of mitochondrial 272 
biogenesis to anti-inflammatory cytokine expression. The Journal of biological 273 
chemistry 286, 16374-16385, doi:10.1074/jbc.M110.207738 (2011). 274 
11 Prochaska, H. J. & Santamaria, A. B. Direct measurement of 275 
NAD(P)H:quinone reductase from cells cultured in microtiter wells: a 276 
screening assay for anticarcinogenic enzyme inducers. Analytical 277 
biochemistry 169, 328-336 (1988). 278 
12 Fahey, J. W., Dinkova-Kostova, A. T., Stephenson, K. K. & Talalay, P. The 279 
"Prochaska" microtiter plate bioassay for inducers of NQO1. Methods in 280 
enzymology 382, 243-258 (2004). 281 
13 Dinkova-Kostova, A. T. et al. Direct evidence that sulfhydryl groups of Keap1 282 
are the sensors regulating induction of phase 2 enzymes that protect against 283 
carcinogens and oxidants. Proc Natl Acad Sci U S A 99, 11908-11913, 284 
doi:10.1073/pnas.172398899 (2002). 285 
14 McMahon, M., Lamont, D. J., Beattie, K. A. & Hayes, J. D. Keap1 perceives 286 
stress via three sensors for the endogenous signaling molecules nitric oxide, 287 
zinc, and alkenals. Proc Natl Acad Sci U S A 107, 18838-18843, 288 
doi:10.1073/pnas.1007387107 (2010). 289 
15 Dinkova-Kostova, A. T., Kostov, R. V. & Canning, P. Keap1, the cysteine-290 
based mammalian intracellular sensor for electrophiles and oxidants. Arch 291 
Biochem Biophys 617, 84-93, doi:10.1016/j.abb.2016.08.005 (2017). 292 
 7 
16 Zhang, D. D. & Hannink, M. Distinct cysteine residues in Keap1 are required 293 
for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by 294 
chemopreventive agents and oxidative stress. Mol Cell Biol 23, 8137-8151 295 
(2003). 296 
17 Linker, R. A. et al. Fumaric acid esters exert neuroprotective effects in 297 
neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134, 298 
678-692, doi:10.1093/brain/awq386 (2011). 299 
18 Tallam, A. et al. Gene Regulatory Network Inference of Immunoresponsive 300 
Gene 1 (IRG1) Identifies Interferon Regulatory Factor 1 (IRF1) as Its 301 
Transcriptional Regulator in Mammalian Macrophages. PLoS One 11, 302 
e0149050, doi:10.1371/journal.pone.0149050 (2016). 303 
19 Naujoks, J. et al. IFNs Modify the Proteome of Legionella-Containing 304 
Vacuoles and Restrict Infection Via IRG1-Derived Itaconic Acid. PLoS Pathog 305 
12, e1005408, doi:10.1371/journal.ppat.1005408 (2016). 306 
20 Guarda, G. et al. Type I interferon inhibits interleukin-1 production and 307 
inflammasome activation. Immunity 34, 213-223, 308 
doi:10.1016/j.immuni.2011.02.006 (2011). 309 
21 Thimmulappa, R. K. et al. Nrf2 is a critical regulator of the innate immune 310 
response and survival during experimental sepsis. J Clin Invest 116, 984-995, 311 
doi:10.1172/JCI25790 (2006). 312 
22 Cordes, T. et al. Immunoresponsive Gene 1 and Itaconate Inhibit Succinate 313 
Dehydrogenase to Modulate Intracellular Succinate Levels. J Biol Chem 291, 314 
14274-14284, doi:10.1074/jbc.M115.685792 (2016). 315 
23 Freigang, S. et al. Nrf2 is essential for cholesterol crystal-induced 316 
inflammasome activation and exacerbation of atherosclerosis. Eur J Immunol 317 
41, 2040-2051, doi:10.1002/eji.201041316 (2011). 318 
24 Dinarello, C. A. Interleukin-1 in the pathogenesis and treatment of 319 
inflammatory diseases. Blood 117, 3720-3732, doi:10.1182/blood-2010-07-320 
273417 (2011). 321 
25 Shen, H. et al. The Human Knockout Gene CLYBL Connects Itaconate to 322 
Vitamin B12. Cell 171, 771-782 e711, doi:10.1016/j.cell.2017.09.051 (2017). 323 
 324 
Figure Legends  325 
 326 
Figure 1. Itaconate activates Nrf2. a-c LPS-induced itaconate (a, n=12, 4 h; b, c 327 
n=5, 24 h). Red and blue dots represent metabolites significantly up- or down-328 
regulated by LPS, respectively. d Reactivity of itaconate with Keap1 thiol group. e, g 329 
LPS-induced Nrf2 (e, 24 h) and Hmox1 (e, 6 h) ± OI. f Nrf2 target gene expression ± 330 
LPS (6 h) ± OI (Nqo1, Gclm, Hmox1 n=12; Gsr, 6Pdg, Taldo1 n=6). h NQO1 activity 331 
in Hepa1c1c7 cells treated as indicated (48 h, n=8). Data are mean ± s.e.m. P values 332 
calculated using one-way ANOVA. Blots are representative of 3 independent 333 
experiments. In the box plots, line shows mean. For gel source data, see 334 
Supplementary Figure 1. 335 
 336 
Figure 2. Itaconate alkylates cysteines. a Itaconate transport by the indicated 337 
carriers (n=4). b Nrf2 and Keap1 protein following co-transfection with Nrf2-V5 ± wild-338 
type or Cys151S mutant Keap1. c MS/MS spectrum of Cys151-containing Keap1 339 
peptide following OI treatment. d Metabolite tracing to itaconate-cysteine adduct ± 340 
LPS (24 h, n=5). e Ldha Cys84 alkylation ± LPS (24 h) or OI (250 μM, 4 h) (n=4). 341 
Data are mean ± s.e.m or S.D. (in a). P values calculated using one-way or two-way 342 
ANOVA for multiple comparisons or two-tailed student t-test for paired comparisons. 343 
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Blots are representative of 3 independent experiments. For gel source data, see 344 
Supplementary Figure 1. 345 
 346 
Figure 3. OI limits IL-1β in an Nrf2-dependent manner and protects against LPS 347 
lethality. a-d LPS (24 h), induced IL-1β mRNA (a, n=3), IL-1β and HIF-1α protein 348 
(b), and ROS and NO production (c, d, n=3, MFI, mean fluorescence intensity) ± OI. 349 
e IL-1β mRNA in PBMCs treated as in a-d (n=3). f Survival, clinical score and body 350 
temperature measurements in mice (n=10) injected i.p ± OI (50 mg/kg, 2 h) ± LPS 351 
(15 mg/kg). g Serum IL-1β and TNF-α from mice i.p. injected ± OI (50 mg/kg, 2 h) ± 352 
LPS (2.5 mg/kg, 2 h, n=3 vehicle, OI; n=15 LPS, OI+LPS). h Nrf2, Hmox1 and IL-1β 353 
protein in wild-type and Nrf2 KO BMDMs treated with LPS (6 h) ± OI. Data are mean 354 
± s.e.m. P values calculated using one-way ANOVA. Blots are representative of 3 355 
independent experiments. For gel source data, see Supplementary Figure 1. 356 
 357 
Figure 4. A feedback loop exists between itaconate and IFN-β. a Metabolite 358 
levels ± IFN-β (1000 U/ml; 27 h; n=5). b LPS (24 h)-induced Irg1 expression ± IFN-β 359 
(1000 U/ml; n=3). c Irg1 expression in wild-type (WT) and IFN receptor (IFNR)-360 
deficient BMDMs ± LPS or poly I:C (40 μg/ml) for 24 h (n=3). d IFN-β (n=3) 361 
expression ± LPS (24 h) ± OI. e ISG15 and IKK-ε ± LPS (24 h) ± OI. f IFN-β protein 362 
expression in PBMCs ± poly I:C (20 μg/ml; 24 h) ± OI (n=3). g Serum IFN-β from 363 
mice i.p. injected ± OI (50 mg/kg, 2 h) ± LPS (2.5 mg/kg; 2 h) (n=3 vehicle, OI; n=15 364 
LPS, OI+LPS). h The anti-inflammatory role of itaconate. Data are mean ± s.e.m. P 365 
values calculated using one-way ANOVA. Blots are representative of 3 independent 366 
experiments. f is representative from one of two human donors. For gel source data, 367 
see Supplementary Figure 1. 368 
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METHODS 369 
 370 
Isolation of Human PBMC 371 
Human PBMC were isolated from human blood using Lymphoprep (Axis-Shield). 30 372 
ml of whole blood was layered on 20 ml lymphoprep and spun for 20 min at 2,000 373 
rpm with no brake on. The PBMCs were isolated from the middle layer. PBMCs were 374 
maintained in RPMI supplemented with 10% (vol/vol) FCS, 2 mM L-glutamine, and 375 
1% penicillin/streptomycin solution. 376 
 377 
Generation of human macrophages 378 
Blood was layered on Histopaque and centrifuged at 800 x g for 20 minutes, 379 
acceleration 9, deceleration at 4. The PBMC layer was isolated and the 380 
macrophages were sorted using magnetic-activated cell sorting (MACS) CD14 beads 381 
Cells were plated at 0.5 x 106 cells/ml in media containing M-CSF (100 ng/ml) and 382 
maintained at 37°C, 5% CO2 for 5 days, to allow differentiation into macrophages. 383 
For further details see the Supplementary Methods section. 384 
 385 
Generation and treatment of bone marrow-derived macrophages (BMDMs) 386 
Mice were euthanized in a CO2 chamber and death was confirmed by cervical 387 
dislocation. Bone marrow cells were extracted from the leg bones and differentiated 388 
in DMEM (containing 10% foetal calf serum, 1% penicillin streptomycin and 20% 389 
L929 supernatant) for 6 days, at which time they were counted and replated for 390 
experiments. Unless stated, 5 X 106 BMDMs/ml were used in in vitro experiments. 391 
Unless stated the LPS concentration used was 100 ng/ml, the DMI and OI 392 
concentration was 125 M and in experiments were pre-treatments prior to LPS 393 
stimulation this was for 3 h.  394 
 395 
Synthesis of Itaconate compounds 396 
For details on synthesis and characterization of chemical compounds details see 397 
Supplementary Methods. 398 
 399 
Metabolomic analysis with Metabolon   400 
Macrophages were plated at 2x106/well in 6-well plates and treated as required 401 
BMDMs, n=5, human macrophages n=12. Analysis was performed by Metabolon. 402 
For further details see the Supplementary Methods section.  403 
Metabolite Measurements for absolute succinate and itaconate quantification 404 
and metabolite tracing 405 
Cells were treated as desired. For tracing studies, immediately prior to LPS 406 
stimulation the media was removed and replaced with DMEM media (1 ml) 407 
containing U-13C-glucose (4.5 g/L) or U-13C-glutamine (584 mg/mL) deplete of 12C- 408 
glucose or 12C-glutamine. Samples were extracted in methanol/acetonitrile/water, 409 
50:30:20 v/v/v (1 ml per 1x106 cells) and agitated for 15 min at 4°C in a Thermomixer 410 
and then incubated at -20°C for 1 h. Samples were centrifuged at maximum speed 411 
for 10 min at 4°C. The supernatant was transferred into a new tube and centrifuged 412 
again at maximum speed for 10 min at 4°C. The supernatant was transferred 413 
autosampler vials. LC-MS analysis was performed using a Q Exactive mass 414 
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spectrometer coupled to a Dionex U3000 UHPLC system (Thermo). For further 415 
details see Supplementary Methods. 416 
 417 
Western blotting 418 
Protein samples from cultured cells were prepared by direct lysis of cells in 5X 419 
Laemmli sample buffer, followed by heating at 95°C for 5 min. For spleen samples, 420 
30 mg of spleen was homogenized in RIPA buffer using the Qiagen TissueLyserII 421 
system. The resulting homogenate was centrifuged at 14000 rpm for 10 min at 4°C, 422 
and supernatants were used for SDS-PAGE. Protein samples were resolved on 8% 423 
or 12% SDS-PAGE gels and were then transferred onto polyvinylidene difluoride 424 
(PVDF) membrane using either a wet or semi-dry transfer system. Membranes were 425 
blocked in 5% (w/v) dried milk in Tris-buffered saline-Tween (TBST) for at least one 426 
hour at room temperature. Membranes were incubated with primary antibody, 427 
followed by the appropriate horseradish peroxidase-conjugated secondary antibody. 428 
They were developed using LumiGLO enhanced chemiluminescent (ECL) substrate 429 
(Cell Signalling). Bands were visualized using the GelDoc system (Biorad). 430 
 431 
Real-time PCR 432 
Total RNA was isolated using the RNeasy Plus Mini kit (Qiagen) and quantified using 433 
a Nanodrop 2000 UV-visible spectrophotometer. cDNA was prepared using 20–100 434 
ng/μl total RNA by a reverse transcription-polymerase chain reaction (RT-PCR) using 435 
a high capacity cDNA reverse transcription kit (Applied Biosystems), according to the 436 
manufacturer’s instructions. Real-time quantitative PCR (qPCR) was performed on 437 
cDNA using SYBR Green probes. qPCR was performed on a 7900 HT Fast Real-438 
Time PCR System (Applied Biosystems) using Kapa fast master mix high ROX 439 
(Kapa Biosystems, for SYBR probes) or 2X PCR fast master mix (Applied 440 
Biosystems, for Taqman probes). For SYBR primer pair sequences see 441 
Supplementary Methods. Fold changes in expression were calculated by the Delta 442 
Delta Ct method using mouse Rps18 as an endogenous control for mRNA 443 
expression. All fold changes are expressed normalized to the untreated control. 444 
 445 
NQO1 bioassay 446 
Inducer potency was quantified by use of the NQO1 bioassay in Hepa1c1c7 murine 447 
hepatoma cells 11,12. Cells (104 per well of a 96-well plate) were grown for 24 h and 448 
treated (n=8) to serial dilutions of compounds for 48 h prior to lysis. NQO1 enzyme 449 
activity was quantified in cell lysates using menadione as a substrate. Protein 450 
concentrations were determined in aliquots from the same cell lysates by the 451 
bicinchoninic acid (BCA) assay (Thermo Scientific). The CD value was used as a 452 
measure of inducer potency. For assays examining the effect of GSH on inducer 453 
potency, 50 μM of each compound was incubated with 1 mM GSH in the cell culture 454 
medium at 37°C for 30 min before treatment. 455 
 456 
Preparation of rat liver mitochondria 457 
Female Wistar rats aged between 10 to 12 weeks (Charles River, UK) were culled by 458 
stunning and cervical dislocation prior to the liver being excised and stored in ice-459 
cold buffer (STE buffer (250 mM sucrose, 5 mM Tris-Cl, 1 mM EGTA (pH 7.4 at 4 460 
°C)). Rat liver mitochondria were isolated by homogenisation and differential 461 
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centrifugation at 4°C in STE buffer26. Briefly, minced tissue was homogenised in STE 462 
buffer before centrifugation (1, 000 x g, 3 min, 4°C) and centrifuging the resulting 463 
supernatant (10, 000 x g, 10 min, 4°C). The mitochondrial pellet was resuspended in 464 
fresh STE before centrifuging (10, 000 x g, 10 min, 4°C). The resulting pellet was 465 
resuspended in STE and assayed for protein concentration via BCA assay (Thermo 466 
Scientific) against a BSA standard curve.  467 
 468 
Preparation of bovine heart mitochondrial membranes 469 
Bovine heart mitochondria were isolated by differential centrifugation in 250 mM 470 
sucrose, 10 mM Tris-Cl, 0.2 mM EDTA (pH 7.8 at 4°C). To prepare membranes, 471 
bovine heart mitochondria were blended with MilliQ water at 4°C before adding KCl 472 
to a final concentration of 150 mM and blending until homogenous. The suspension 473 
was centrifuged (13, 500 x g, 40 min, 4°C) and the pellet resuspended in re-474 
suspension buffer (20 mM Tris-Cl, 1 mM EDTA, 10% glycerol, pH 7.55 at 4°C) before 475 
homogenisation and assaying for protein by BCA assay (Thermo Scientific)27. 476 
 477 
Measuring complex II+III activity 478 
Bovine heart mitochondrial membranes (80 µg protein/ml) were incubated in 50 mM 479 
potassium phosphate buffer (50 mM potassium phosphate, 1 mM EDTA, pH 7.4, 480 
4°C) supplemented with 3 mM KCN, 4 µM rotenone and succinate. In a 96-well 481 
microplate, inhibitor or vehicle control and membrane incubation were plated and 482 
incubated for 10 minutes at 30°C. Alternatively, where indicated, itaconate was 483 
incubated with membranes and removed by twice centrifuging membranes and 484 
resuspending in non-itaconate containing buffer, prior to plating with 1 mM succinate. 485 
Oxidised cytochrome-c was added prior to measuring the respiratory chain activity by 486 
assessing the reduction of cytochrome-c spectrophotometrically at 550 nm at 20 487 
second intervals for 5 min at 30°C. Final concentrations were 10 µg protein/well 488 
bovine heart membranes and 30 µM ferricytochrome c. 489 
 490 
Measuring rat liver mitochondrial respiration 491 
Respiration of rat liver mitochondria was assessed with an Oxygraph-2K 492 
(OROBOROS instruments high resolution respirometry, Austria). Rat liver 493 
mitochondria (0.5 mg mitochondrial protein/ml) were added to KCl buffer (pH 7.2, 494 
37°C) and respiration assessed in the presence of 4 µg/ml rotenone, 1 mM 495 
succinate, 1 µM FCCP and inhibitors or buffer control. 496 
 497 
Assessing itaconate ester reactivity with glutathione 498 
1 or 5 mM GSH and 5 mM itaconate esters or vehicle control were incubated in KCl 499 
buffer (pH 7.2 or 8) at 37°C for 2 hours, where indicated, 10 µg recombinant 500 
glutathione-S-transferase (GST) was added to the incubation. The reaction was 501 
stopped by acidification with 5% sulfosalicylic acid prior to assessing glutathione 502 
content by the GSH recycling assay as described previously 28. 503 
 504 
Itaconate transport assays 505 
Itaconate transport by mitochondrial carriers was assessed as described previously 506 
29. For further details see the Supplementary Methods section.  507 
 508 
Cell uptake of itaconate 509 
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C2C12 mouse myoblasts were plated at 300,000 cells/well in a 6-well plate in 510 
complete growth medium and adhered overnight in a humidified 5% CO2, 37°C 511 
incubator. The following day, media was replaced with serum free DMEM containing 512 
itaconate esters and cells were treated for 30 minutes at 37°C. Cells were extracted 513 
as described above (method for succinate quantification), with MS internal standard 514 
(100 pmoles) added and stored at -80°C prior to LC-MS/MS analysis. For further 515 
details see Supplementary Methods. 516 
 517 
LC-MS/MS analysis was performed using an LCMS-8060 mass spectrometer 518 
(Shimadzu) with a Nexera X2 UHPLC system (Shimadzu). For further details see 519 
Supplementary Methods 520 
 521 
Keap1 cysteine target validation  522 
COS1 cells (2.5 x 105 per well) in 6-well plates were co-transfected (Lipofectamine 523 
2000) with 0.8 µg of Nrf2-V5 and 1.6 µg of wild-type or Cys151S mutant Keap114, or 524 
1.6 µg of pcDNA. Cells were grown for 21 h then treated with 20 or 100 µM OI, 5 µM 525 
sulforaphane (SFN) or 0.1% acetonitrile (ACN, vehicle) for 3 h. Cell were washed in 526 
PBS and lysed in 200 µl of SDS-lysis buffer [50 mM Tris-HCl pH 6.8, 2% (w/v) 527 
sodium dodecyl sulfate (SDS) and 10% (v/v) Glycerol]. Lysates were sonicated (20 528 
sec at 30% amplitude using Vibra-Cell ultrasonic processor, Sonic) and boiled (3 529 
min), DTT and Bromophenol blue were added up to 0.1M and 0.02% (w/v) final 530 
concentrations, respectively. Proteins (10 µg) were resolved on a gradient (4-12%) 531 
NuPAGE SDS gel, transferred onto nitrocellulose membranes, and immunoblotted 532 
with anti-Keap1 (rat monoclonal, Merk Millipore, clone 144), anti-Nrf2 (rabbit 533 
monoclonal, CST), and anti--actin (mouse monoclonal, Sigma) antibodies. HRP- or 534 
IRDye-labelled secondary antibodies were used interchangeably, followed by either 535 
ECL-detection or scanning using Odyssey imager (Li-COR).    536 
 537 
Enzyme-linked immunosorbent assay (ELISA) 538 
Cytokine concentrations in cell supernatants were measured using enzyme-linked 539 
immunosorbent assay (ELISA) Duoset kits for mouse IL-10 and TNF-α and human 540 
IFN-β and IL-1β, according to the manufacturer’s instructions. Cytokine 541 
concentrations in serum samples isolated from whole blood were measured using 542 
Quantikine ELISA kits for mouse or human IL-1β, IFN-β IL-10 and TNF-α. Duoset 543 
and Quantikine kits were from R&D Systems. Optical density values were measured 544 
at a wavelength of 450 nm, using a FLUOstar Optima plate reader (BMG Labtech). 545 
Concentrations were calculated using a 4-parameter fit curve.  546 
 547 
FACS Analysis of reactive oxygen species (ROS) 548 
BMDMs were seeded at 0.5x106 cells/ml and treated as normal. 2 hours prior to 549 
staining, 100% EtOH was added to the dead cell control well. 30 minutes prior to the 550 
end of the stimulation, CellROX (5 μM) was added directly into the cell culture 551 
medium. Supernatants of cells that were to be stained with Aqua Live/Dead were 552 
removed, and an Aqua Live/Dead dilution (1 ml; 1 in 1000 in PBS) was added to 553 
each well. Cells were incubated in tinfoil at 37°C for 30 min. Cells were washed with 554 
PSB, scraped in PBS (0.5 ml), and transferred to polypropylene FACS tubes. 555 
Samples were analyzed using a Dako CyAn flow cytometer, and data was analyzed 556 
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using FlowJo software. Mean fluorescence intensity (MFI) was quantified as a 557 
measure of cellular ROS production. 558 
 559 
NO assay 560 
Nitric oxide concentrations in cell supernatants were measured using Greiss reagent 561 
assay kit from Thermo Fischer Scientific according to the manufacturer’s instructions. 562 
Optical density values were measured at a wavelength of 548 nm, using a SoftMax 563 
Pro plate reader. Concentrations were calculated using a linear standard curve. 564 
 565 
GSH/GSSG measurements 566 
BMDMs were plated at 0.1x106 cells/ml in opaque 96-well plates. Cells were pre-567 
treated with OI (125 M) for 2 h and then stimulated with H2O2 (100 M) for 24h. 568 
After 24 h cell media was removed and GSH/GSSG was quantified using MyBio 569 
GSH/GSSG-Glo Assay (V6611) as per manufacturer’s instructions. Luminescence 570 
was quantified using a FLUOstar Optima plate reader. 571 
 572 
LDH assay 573 
Cells were plated at 0.5x106 cells/ml in white 24-well plates (500 μl/well) and treated 574 
as required. Cytotoxicity, as determined by LDH release, was assayed using 575 
CytoTox96 Non-radioactive Cytotoxicity Assay kit (Promega) according to the 576 
manufacturer’s instructions. 577 
 578 
Seahorse analysis of lactate production 579 
Cells were plated at 0.2x106 cells/well of a 24-well Seahorse plate. Cells were treated 580 
and stimulated as normal. A utility plate containing calibrant solution (1 ml/well) was 581 
placed in a CO2-free incubator at 37°C overnight. The following day media was 582 
removed from cells and replaced with glucose-supplemented XF assay buffer (500 583 
μl/well) was placed in a CO2-free incubator for at least 0.5 h. Inhibitors (Oligomycin, 584 
carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP), 2DG, Rotenone; 70 585 
μl) were added to the appropriate port of the injector plate. This plate together with 586 
the utility plate was run on the Seahorse for calibration. Once complete, the utility 587 
plate was replaced with the cell culture plate and run on the Seahorse XF-24.   588 
 589 
Endotoxin-induced model of sepsis 590 
For cytokine measurements mice were treated intraperitoneally (i.p.) ± OI (50 mg/kg) 591 
in 40% cyclodextrin in PBS or vehicle control for 2 h prior to stimulation with LPS 592 
(Sigma; 2.5 mg/kg) i.p. for 2 h. Mice were euthanized in a CO2 chamber, blood 593 
samples were collected and serum was isolated. Cytokines were measured using 594 
R&D ELISA kits according to manufactures protocol. For temperature recording mice 595 
(n=10 per group) were treated i.p. ± OI (50 mg/kg) in 40% cyclodextrin in PBS or 596 
vehicle control for 2 h prior to stimulation with LPS (5 mg/kg) and monitored for 597 
temperature at 1, 2, 3, 4, 6, 12, 18 and 24 hours post LPS. Temperature was 598 
monitored using subcutaneously implanted temperature transponder chips (Bio 599 
Medic Data Systems; IPTT 300) which were injected between the shoulder blades 48 600 
hours prior to experiment. At defined time body temperature was measured by 601 
scanning the transponder with a corresponding BMDS Smart Probe. Animals were 602 
additionally monitored for clinical signs of endotoxic shock, based on temperature 603 
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change, body condition, physical condition and unprovoked behavior, with a 604 
combined score of 9 indicating the humane end point for the experiment. 605 
 606 
siRNA transfection of BMDMs 607 
Cells were plated at 1x106 cells/ml in 12 well plates overnight. On the day of 608 
transfection the media was replaced with 500 μl DMEM without P/S or FBS. Two 609 
eppendorfs/siRNA were prepared. Optimem (250 μl/well) was added to each tube. 610 
RNAimax (add 5 μl/well) was added to one set of tubes and siRNA (50 nM/well) was 611 
added to the second set of tubes. The tubes containing the siRNA was added to the 612 
tube with RNAimax, mixed well by pipetting and incubated for 15 min. The mix (500 613 
μl) was added to each well. 24 h post transfection cells were treated as required.  614 
 615 
Analysis of Keap1 modification by OI 616 
Human embryonic kidney cells (HEK293Ts) were transfected with a pCMV6-Keap1 617 
vector (Myc-DDK-tagged mouse Keap1) (OriGene). 24 h post-transfection, cells were 618 
treated with OI (500 µM) or vehicle control (PBS) for 4 h. Tagged-Keap1 was 619 
immunoprecipitated using an anti-FLAG antibody (Sigma) and protein A/G beads 620 
(Santa Cruz). After immunoprecipitation, bound Keap1 was eluted off the beads 621 
using FLAG peptide (500 µl; 200 µg/ml) (Sigma) diluted in 1X TBS pH 7.4. The 622 
samples were then concentrated and the FLAG peptide removed using 10K 623 
centrifugation filter columns (Merck). The concentrated samples were then divided in 624 
half for downstream processing. One half of each sample was diluted 1 in 2 with 5X 625 
SDS sample buffer and separated using SDS-PAGE (Bio-Rad). Overexpressed 626 
Keap1 was detected using Coomassie blue staining and the corresponding bands 627 
were excised from the gel and subjected to in-gel digest as described. Briefly, the gel 628 
slices were cut into smaller pieces (1-2 mm3) prior to reduction with DTT (10 mM) 629 
and alkylation with IAA (50 mM). Half of the gel slices from each sample were then 630 
subjected to a trypsin (2 µg) digest, the other half were digested with elastase (1 µg) 631 
overnight at 37°C. Similarly, the remaining sample concentrates (in solution) were 632 
reduced with DTT and alkylated with IAA, prior to precipitation of the protein via the 633 
methanol-chloroform extraction method. The protein pellet was re-suspended in urea 634 
(6 M), which was then diluted to <1 M urea with ultrapure H2O. The samples were 635 
then digested with trypsin (2 µg) overnight at 37°C. Digested protein samples were 636 
analysed in an Orbitrap Fusion Lumos coupled to a UPLC ultimate 3000 RSLCnano 637 
System (both Thermo Fisher). For further details see Supplementary Methods. 638 
 639 
Assessment of cysteine alkylation by itaconate using Iodo-TMT 640 
Following treatment cells were lysed in HEPES pH 7.5, EDTA, glycerol and NP40. 2 641 
mM TCEP and 50 mM NEM were added in a buffer containing 50 mM HEPES, 2% 642 
SDS, 125 mM NaCl, pH 7.2 and samples were incubated for 60 min at 37 °C in the 643 
dark to reduce and alkylate all unmodified protein cysteine residues. 20% (v/v) TCA 644 
was added to stabilize thiols and incubated overnight at 4°C and then pelleted for 10 645 
min at 4000 g at 4 °C. The pellet was washed with 3 times with cold methanol (2 ml) 646 
and then resuspended in 2 ml 8 M urea containing 50 mM HEPES (pH 8.5). Protein 647 
concentrations were measured by BCA assay (Thermo Scientific) prior to protease 648 
digestion. Protein lysates were diluted to 4 M urea and digested with LysC (Wako, 649 
Japan) in a 1/100 enzyme/protein ratio and trypsin (Promega) at a final 1/200 650 
enzyme/protein ratio for 4 hours at 37 °C. Protein extracts were diluted further to a 651 
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2.0 M urea and LysC (Wako, Japan) at 1/100 enzyme/protein ratio and trypsin 652 
(Promega) at a final 1/200 enzyme/protein ratio were added again and incubated 653 
overnight at 37 °C. Protein extracts were diluted further to a 1.0 M urea 654 
concentration, and trypsin (Promega) was added to a final 1/200 enzyme/protein 655 
ratio for 6 hours at 37 °C. Digests were acidified with 250 μL of 25% acetic acid to a 656 
pH ~2, and subjected to C18 solid-phase extraction (50 mg Sep-Pak, Waters). 6-7 M 657 
excess TMT label was added to each digest for 30 min at room temperature 658 
(repeated twice). The reaction was quenched using 4 uL of 5% hydroxylamine. 659 
Samples were subjected to an additional C18 solid-phase extraction (50 mg Sep-660 
Pak, Waters). For LC-MS/MS parameters, Data processing and MS2 spectra 661 
assignment, TMT reporter ion intensities and quantitative data analysis see 662 
Supplementary Methods.  663 
 664 
Reagents 665 
For a complete list of reagents see Supplementary Methods.  666 
 667 
Mouse strains  668 
Wild type C57Bl/6 mice were from Harlan U.K. and Harlan Netherlands. Animals 669 
were maintained under specific pathogen-free conditions in line with Irish and 670 
European Union regulations. Experiments were approved by local ethical review and 671 
were carried out under the authority of Ireland’s project license. All animal studies 672 
performed in GSK were ethically reviewed and carried out in accordance with 673 
Animals (Scientific Procedures) Act 1986 and the GSK Policy on the Care, Welfare 674 
and Treatment of Animals.” Nrf2-deficient mice and their wild type counterparts, both 675 
on the C57Bl/6 genetic background (used for isolation of BMDM cells) were bred and 676 
maintained in the Medical School Resource Unit of the University of Dundee. 677 
 678 
Statistical analysis 679 
Data were expressed as mean ± s.e.m. and P values were calculated using two-680 
tailed Student’s t-test for pairwise comparison of variables, one-way ANOVA for 681 
multiple comparison of variables, and two-way ANOVA involving two independent 682 
variables. A Sidak’s multiple comparisons test was used. A confidence interval of 683 
95% was used for all statistical tests. Sample sizes were determined on the basis of 684 
previous experiments using similar methodologies. For all experiments, all stated 685 
replicates are biological replicates. For in vivo studies, mice were randomly assigned 686 
to treatment groups. For MS analyses, samples were processed in random order and 687 
experimenters were blinded to experimental conditions.    688 
 689 
Data Availability  690 
Full scans for all western blots have been provided in the Supplementary Figures. 691 
Source Data for all mouse experiments have been provided. All other data are 692 
available from the corresponding author on reasonable request. 693 
 694 
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 709 
Extended Data Figure 1. The effect of itaconate on CII activity. a Complex II+III 710 
activity in bovine heart mitochondrial membranes incubated with succinate ± 711 
malonate or itaconate (n=3 independent experiments). b Effect of malonate or 712 
itaconate on oxygen consumption rate of rat liver mitochondria in the presence of 713 
succinate (1 mM) and FCCP (1 µM; n=3 independent experiments). c, d Complex 714 
II+III activity in bovine heart mitochondrial membranes incubated with itaconate (1 715 
mM unless indicated), with subsequent removal and addition of succinate (1 mM; 716 
n=3 independent experiments). Data are mean ± s.e.m, n=3 independent 717 
experiments. P values calculated using one or two-way ANOVA. 718 
 719 
Extended Data Figure 2. DMI activates Nrf2 and limits cytokine production. a, c 720 
LPS (100 ng/ml)-induced Nrf2 (a, 24 h) and Hmox1 (c, 6 h) protein expression ± 721 
DMI. b Nrf2-dependent mRNA expression ± LPS (6 h) ± DMI (n=3). d GSH and 722 
GSSG levels ± LPS ± DMI (n=5). e, f LPS (24 h)-induced IL-1β mRNA (e), IL-1β and 723 
HIF-1α protein (f) expression ± DMI (n=3). Data are mean ± s.e.m. P values 724 
calculated using one-way ANOVA. Blots are representative of 3 independent 725 
experiments. For gel source data, see Supplementary Figure 1. 726 
 727 
Extended Data Figure 3. OI is the best tool to assess itaconate-dependent Nrf2 728 
activity. a Reactivity of DMI, itaconate and OI with thiols. b, c Itaconate ester 729 
reactivity with GSH ± GST as detailed in Methods (n=3). d Itaconate levels in C2C12 730 
cells ± itaconate esters (n=3). e, i Itaconate or GSH levels ± LPS (6 h) ± OI (n=5). f 731 
NQO1 activity in Hepa1c1c7 cells treated with DMI or OI (48 h) ± GSH (n=8). g, h 732 
Metabolic intermediates in glutathione (GSH) synthesis (h, average of 5 biological 733 
replicates). i GSH levels ± LPS (6 h) ± OI (n=5). j GSH/GSSG ± OI (2 h) ± H2O2 (100 734 
µM, 24 h; n=3). k Hmox protein levels ± OI ± H2O2 (24 h). l Nrf2, Hmox and IL-1β 735 
protein levels in BMDMs pre-treated with OI, 4-octyl 2-methylsuccinate (OMS) or 736 
octyl succinate (OS), all 125 µM for 3 h ± LPS (6 h). m LPS-induced Nrf2 (24 h) and 737 
Hmox1 (6 h) protein expression ± dimethyl malonate (DMM). Data are mean ± s.e.m. 738 
P values calculated using one- or two-way ANOVA. Blots are representative of 3 739 
independent experiments. For gel source data, see Supplementary Figure 1. 740 
 741 
Extended Data Figure 4. Itaconate is transported by the mitochondrial 742 
oxoglutarate, dicarboxylate and citrate carriers. a Itaconate uptake into vesicles 743 
of Lactococcus lactis membranes expressing indicated carriers loaded with itaconate 744 
(1 mM), and transport initiated by the addition of [3H]-itaconate (1 μM). b Initial 745 
transport rates of each carrier with either canonical substrate (homo-exchange) or 746 
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canonical substrate/itaconate (hetero-exchange). Results are presented as n=4 747 
independent experiments ± S.D. P values calculated using 2-tailed student t-test.  748 
 749 
Extended Data Figure 5. Keap1 is alkylated by OI on major redox sensing 750 
cysteines. a Modification of cysteine by fumarate or itaconate. MS/MS spectrum of 751 
Keap1 Cys257 (b), Cys257 (c) and Cys288 (d) peptides indicating alkylation of these 752 
sites with OI treatment (left) but not in the corresponding carbamidomethylated 753 
(CAM) peptides (right). e, f Ldha Cys84 alkylation ± LPS (e, 24 h) or OI (f, 250 μM, 4 754 
h) (n=4). Detected N- and C-terminal fragment ions of both peptides are assigned in 755 
the spectrum and depicted as follows: b: N-terminal fragment ion; y: C-terminal 756 
fragment ion; *: fragment ion minus NH3; 0 or *: fragment ion minus H2O; and 2+: 757 
doubly charged fragment ion. Representative of 1 independent experiment. 758 
 759 
Extended Data Fig 6. Identification of an itaconate-cysteine adduct. 13C6-glucose 760 
(a-c) or 13C5-glutamine (d-e) labelling experiment tracking itaconate-cysteine adduct 761 
formation in BMDMs treated with LPS (n=5; 24 h). b, e represent % isotopologue of 762 
the total pool. c, f represent changes in the total pool ± LPS treatment. Data are 763 
mean ± s.e.m, for 5 replicates. P values calculated using two-way ANOVA. 764 
 765 
Extended Data Figure 7. OI decreases LPS-induced cytokine production, 766 
ECAR, ROS and NO. a % cytotoxicity in BMDMs ± LPS ± OI (n=3). b LPS-induced 767 
ECAR ± OI, analysed on the Seahorse XF-24 in BMDMs (representative trace of 768 
n=3). c, d LPS-induced IL-10 mRNA (c, 4 h) and protein (d, 24 h) and TNF-α protein 769 
(f; n=7) ± OI (n=3). e pp65 protein levels ± LPS ± OI. h Representative gating 770 
strategy for FACS analysis of ROS production in cells as treated in d (representative 771 
image of n=3). i LPS-induced Nos2 expression (n=6) ± OI. j LPS-induced TNF-α 772 
(n=4) and IL-1β (n=3) protein levels ± OI in PBMCs. k Nrf2 and hmox1 protein levels 773 
(m=mouse) or Nrf2-dependent gene expression (n=5) in peritoneal macrophages 774 
from mice i.p. injected ± OI (50 mg/kg, 6 h). l Serum IL-10 from mice i.p. injected ± OI 775 
(50 mg/kg, 2 h) ± LPS (2.5 mg/kg, 2 h, n=3 vehicle, OI; n=15 LPS, OI+LPS). Data are 776 
mean ± s.e.m. P values calculated using one-way ANOVA. Blots are representative 777 
of 3 independent experiments. For gel source data, see Supplementary Figure 1. 778 
 779 
Extended Data Figure 8. The effects of OI on cytokine production are Nrf-2-780 
dependent. a-e: Nrf2, Hmox1, IL-1β protein (a, c, d) and IL-1β mRNA (b, e) 781 
expression in BMDMs transfected with two different Nrf2 (50 nM) siRNAs compared 782 
with non-silencing control ± LPS (6 h; a, b, d) or (24 h; c, d, e) ± OI (n=6). f IL-1β 783 
mRNA expression in wild-type and Nrf2 KO BMDMs treated with LPS (24 h; WT 784 
(n=2) and Nrf2 KO (n=4)) ± OI. IL-1β (g), Nos2 (j) mRNA and IL-1β (h), IL-10 (i), 785 
TNF-α and NO (k) protein ± LPS (24 h) ± diethyl maleate (DEM; 100 μM) or 15-786 
Deoxy-Δ12,14-prostaglandin J2 (J2; 5 μM) pretreatment for 3 h (n=3). Data are mean 787 
± s.e.m. P values calculated using one-way ANOVA. Blots are representative of 3 788 
independent experiments. For gel source data, see Supplementary Figure 1.  789 
 790 
Extended Data Figure 9. An Nrf2-dependent feedback loop exists between 791 
itaconate and IFN-β. a Metabolite levels ± IFN-β (1000 U/ml; 27 h; n=5). b, c Isg20 792 
and Irf5 mRNA expression in BMDMs treated with LPS (b) or poly I:C (c, 40 μg/ml; 793 
24 h) ± OI (n=6). d IL-10 mRNA (n=3) and protein (n=5) expression ± LPS for 4 h 794 
 18 
(left panel) or 24 h (right panel) ± IFN-β treatment (1000 U/ml) for 3 h. e Isg20 795 
expression in BMDMs transfected with two different Nrf2 (50 nM) siRNAs compared 796 
with non-silencing control ± LPS (6 h) ± OI (n=6). f ISG20 mRNA expression in WT 797 
(n=2) and Nrf2 KO (n=4) BMDMs ± LPS (6 h) ± OI. g ISG20 mRNA expression ± 798 
LPS (24 h) ± diethyl maleate (DEM; 100 μM) or 15-Deoxy-Δ12,14-prostaglandin J2 799 
(J2; 5 μM) pretreatment for 3 h (n=3). Data are mean ± s.e.m, P values calculated 800 
using one-way ANOVA. 801 
 802 
Extended Data Table 1. Mass spectrometry analysis of itaconate-induced cysteine 803 
alkylation. a Cysteine/Lysine Residue(s) in Keap1 modified by OI as determined by 804 
tandem mass spectrometry. b Cysteine residues modified by itaconate in BMDMs 805 
treated with LPS identified using tandem mass spectrometry. c Cysteine residues 806 
modified by itaconate in BMDMs treated with OI identified using tandem mass 807 
spectrometry 808 
 809 
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